Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
First RNA Antagonist Medicine to Be Tested in Patients Reduces Severity of Adult Leukaemia Copenhagen, 6th June 2007 - Santaris Pharma, the Danish biopharmaceutical company, announced today that SPC2996, the Company's new RNA Antagonist of Bcl-2, has shown early evidence of efficacy in an initia...Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
... own development activities within metabolic disorders and infectious diseases, it has been decided to divest the activities within the development of spc2996 targeting CLL. This process is ongoing. EZN3042-Survivin In February 2009 Santaris Pharma's collaboration partner Enzon Pharmaceuticals ...News - FDA Approves IND for SPC2996 in Chronic Lymphocytic Leukaemia
SPC2996 is the first of a new class of LNA-based investigational drugs known as ... SPC2996 acts by inhibiting the synthesis of Bcl-2, a key intracellular protein ...Definition of oligonucleotide SPC2996 - National Cancer Institute Drug ...
The search textbox has an autosuggest feature. ... Oligonucleotide SPC2996 binds to and inactivates Bcl-2 mRNA, thereby inhibiting ...SPC2996 in Chronic Lymphocytic Leukaemia - Full Text View ...
SPC2996 in Chronic Lymphocytic Leukaemia. This study is ongoing, but not recruiting participants. ... Dose Escalating, Phase I/II Study of SPC2996,an LNA ...Investigational New Drug Application Approved for SPC2996 for Treatment ...
SPC2996 is an RNA antagonist that has been designed to reduce Bcl-2 protein ... II study is currently ongoing to evaluate SPC2996 in relapsed or refractory CLL. ...Santaris Pharma presents positive preclinical data on SPC2996 at the ...
SPC2996 was tested for anti-leukaemic activity over two weeks in this model ... Therapy with SPC2996 resulted in a 54% reduction (p=0.043) in the number of CLL ...